Efficacy and safety of onabotulinumtoxinA for treatment of pediatric upper limb spasticity: Primary results
Sign Up to like & getrecommendations! Published in 2018 at "Toxicon"
DOI: 10.1016/j.toxicon.2018.11.080
Abstract: the authors by Karen Pemberton, PhD, of Evidence Scientifi c Solutions, Inc, and funded by Allergan plc. All authors met the ICMJE authorship criteria. Neither honoraria nor payments were made for authorship. Financial arrangements of… read more here.
Keywords: efficacy safety; allergan plc; treatment pediatric; neurotoxin association ... See more keywords
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.068
Abstract: Abstract Background ABSSSIs are common in patients with diabetes and have an increased risk of complications. Dalbavancin is a long-acting lipoglycopeptide with potent activity against Gram-positive pathogens responsible for ABSSSI, including methicillin-resistant Staphylococcus aureus (MRSA),… read more here.
Keywords: patients diabetes; allergan plc; plc employee; skin ... See more keywords
1848-P: Insulin Sensitivity and Metabolic Profile of Subjects with Type 2 Diabetes and Nonalcoholic Steatohepatitis after Exposure to Cenicriviroc: A Subanalysis of the CENTAUR Study
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-1848-p
Abstract: Introduction: In mice, C-C motif chemokine receptor (CCR)5 deletion protects against insulin resistance, hepatic steatosis, and glucose intolerance. We aimed to characterize the metabolic effects of cenicriviroc (CVC), a potent CCR2/5 inhibitor, in type 2… read more here.
Keywords: nonalcoholic steatohepatitis; allergan plc; self allergan; type diabetes ... See more keywords